| Sorafenib in advanced clear-cell renal-cell carcinoma B Escudier, T Eisen, WM Stadler, C Szczylik, S Oudard, M Siebels, ... New England Journal of Medicine 356 (2), 125-134, 2007 | 6094 | 2007 |
| Discovery and development of sorafenib: a multikinase inhibitor for treating cancer S Wilhelm, C Carter, M Lynch, T Lowinger, J Dumas, RA Smith, ... Nature reviews Drug discovery 5 (10), 835-844, 2006 | 2108 | 2006 |
| Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus MJ Roman, BA Shanker, A Davis, MD Lockshin, L Sammaritano, ... New England Journal of Medicine 349 (25), 2399-2406, 2003 | 1767 | 2003 |
| Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma MJ Ratain, TIM Eisen, WM Stadler, KT Flaherty, SB Kaye, GL Rosner, ... Journal of Clinical Oncology 24 (16), 2505-2512, 2006 | 1313 | 2006 |
| Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis T Eisen, T Ahmad, KT Flaherty, M Gore, S Kaye, R Marais, I Gibbens, ... British journal of cancer 95 (5), 581-586, 2006 | 799 | 2006 |
| Activation of cultured vascular endothelial cells by antiphospholipid antibodies. R Simantov, JM LaSala, SK Lo, AE Gharavi, LR Sammaritano, JE Salmon, ... The Journal of clinical investigation 96 (5), 2211-2219, 1995 | 529 | 1995 |
| Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo Q Ling, AT Jacovina, A Deora, M Febbraio, R Simantov, RL Silverstein, ... The Journal of clinical investigation 113 (1), 38-48, 2004 | 465 | 2004 |
| The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome O Amengual, T Atsumi, MA Khamashta, GRV Hughes Thrombosis and haemostasis 79 (02), 276-281, 1998 | 349 | 1998 |
| High affinity binding of β2-glycoprotein I to human endothelial cells is mediated by annexin II K Ma, R Simantov, JC Zhang, R Silverstein, KA Hajjar, KR McCrae Journal of Biological Chemistry 275 (20), 15541-15548, 2000 | 290 | 2000 |
| Body mass index and metastatic renal cell carcinoma: clinical and biological correlations L Albiges, AA Hakimi, W Xie, RR McKay, R Simantov, X Lin, JL Lee, ... Journal of Clinical Oncology 34 (30), 3655-3663, 2016 | 225 | 2016 |
| Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer AAN Rose, AA Grosset, Z Dong, C Russo, PA MacDonald, NR Bertos, ... Clinical cancer research 16 (7), 2147-2156, 2010 | 220 | 2010 |
| Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma U Gatzemeier, G Blumenschein, F Fosella, R Simantov, J Elting, ... Journal of Clinical Oncology 24 (18_suppl), 7002-7002, 2006 | 210 | 2006 |
| Naloxonazine actions in vivo GSF Ling, R Simantov, JA Clark, GW Pasternak European journal of pharmacology 129 (1-2), 33-38, 1986 | 205 | 1986 |
| Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis RM Bukowski, T Eisen, C Szczylik, WM Stadler, R Simantov, M Shan, ... Journal of Clinical Oncology 25 (18_suppl), 5023-5023, 2007 | 204 | 2007 |
| Genetic background determines the extent of atherosclerosis in ApoE-deficient mice HM Dansky, SA Charlton, JL Sikes, SC Heath, R Simantov, LF Levin, ... Arteriosclerosis, thrombosis, and vascular biology 19 (8), 1960-1968, 1999 | 199 | 1999 |
| Differential development of acute tolerance to analgesia, respiratory depression, gastrointestinal transit and hormone release in a morphine infusion model GSF Ling, D Paul, R Simantov, GW Pasternak Life sciences 45 (18), 1627-1636, 1989 | 175 | 1989 |
| Change in neutrophil-to-lymphocyte ratio in response to targeted therapy for metastatic renal cell carcinoma as a prognosticator and biomarker of efficacy AJ Templeton, JJ Knox, X Lin, R Simantov, W Xie, N Lawrence, R Broom, ... European urology 70 (2), 358-364, 2016 | 169 | 2016 |
| NFκB is an essential intermediate in the activation of endothelial cells by anti-β2-glycoprotein 1 antibodies S Dunoyer-Geindre, P de Moerloose, B Galve-de Rochemonteix, G Reber, ... Thrombosis and haemostasis 88 (11), 851-857, 2002 | 157 | 2002 |
| The antiangiogenic effect of thrombospondin-2 is mediated by CD36 and modulated by histidine-rich glycoprotein R Simantov, M Febbraio, RL Silverstein Matrix Biology 24 (1), 27-34, 2005 | 143 | 2005 |
| Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): impact of crossover on survival T Eisen, RM Bukowski, M Staehler, C Szczylik, S Oudard, WM Stadler, ... Journal of Clinical Oncology 24 (18_suppl), 4524-4524, 2006 | 141 | 2006 |
